John Marshall News
-
When Mobil Corp. quit midtown Manhattan for 130 green acres in Fairfax County, Virginia, its new neighbors included country stores, dairy farms and a highway that ringed the nation’s capital. Mobil brought hope that the suburb could break free of its Washington ties to build its own world-class economy.
-
Lauren Paul, who won a national championship as the women’s lacrosse coach at Franklin & Marshall College, was fired by the Lancaster, Pennsylvania, school after an investigation into a hazing complaint.
-
When Barack Obama takes the oath of office next week, he will look into the eyes of a man who has shaped the 44th president’s legacy like no one else.
-
John Marshall Law School in Chicago and the Maurice A. Deane School of Law at Hofstra University were among a group of law schools sued over claims they misrepresented employment data, leaving graduates with mounting debt and limited job prospects.
-
Investors should buy bullish Apple Inc., Coca-Cola Co. and Verizon Communications Inc. options because those companies depend less on economic growth, which is projected to slow this year, Goldman Sachs Group Inc. said.
-
The Supreme Court is much on Mitch McConnell’s mind these days. The Senate minority leader, a Kentucky Republican, just finished reading Jean Edward Smith’s biography of the great Chief Justice John Marshall.
-
For Joe McGlynn, executive vice president at Campbell Fittings Inc. in Boyertown, Pennsylvania, the benefits of a tax incentive to spur business investment are clear.
-
The U.S. Supreme Court will hear echoes of its health-care arguments as it reviews Arizona’s illegal-immigrant crackdown, a law that inspired similar moves across the country and sparked a confrontation with President Barack Obama.
-
Erika Ovalle joined several dozen activists in the Phoenix heat outside the Immigration and Customs Enforcement office to protest the U.S. Supreme Court decision they say opens the door to racial profiling in Arizona.
-
Investors should buy Bristol-Myers Squibb Co. calls as approval for a melanoma treatment may boost the drugmaker’s stock price, Goldman Sachs Group Inc. said.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page